Intimation of Earnings Call

July 21, 2026 To, To, National Stock Exchange of India Limited, BSE Limited, “Exchange Plaza”, Corporate Relationship Department, 5th Floor, Plot No. C/1, G Block, 2nd Floor, New Trading Ring, Bandra- Kurla Complex Bandra (East), Mumbai P.J. Towers, Dalal Street, – 400 051 Mumbai – 400 001 NSE Symbol: GLENMARK Scrip Code: 532296 ISIN: INE935A01035 ISIN: INE935A01035 Our Reference No. 32/26-27 Our Reference No. 32/26-27 Dear Sir/ Madam, Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Intimation of Earnings Call With reference to the captioned subject and pursuant to Regulation 30 and Para A of Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Earnings Call on Unaudited Financial Results for the quarter ended June 30, 2026, is scheduled to be held as per the details below: Day Monday Date August 03, 2026 Time 8:30 am – 9:30 am [IST] Request you to kindly take the same on record. Thanking You. Yours faithfully, For Glenmark Pharmaceuticals Limited Rashmi Khandelwal Company Secretary & Compliance Officer ACS - 28839 Encl: As above Glenmark Pharmaceuticals Limited Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com I N V I T A T I O N Glenmark Pharmaceuticals Ltd. Q1 FY 2027 Results Earnings Call Date: Monday, 03 August 2026 Time: 8:30 am – 9:30 am [IST] Dial – in Numbers: Universal Access Number: +91 22 6280 1298 +91 22 7115 8199 USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448 To pre-register online, please click here For any clarification, please contact: Utkarsh Gandhi E-mail: utkarsh.gandhi3@glenmarkpharma.com Phone: +91 22 4018 9232